References (continued)

26. Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer.& Lancet. 2006;367(9510):595–604.

Continue Reading

27. Auvinen A, Curtis RE, Ron E. Risk of subsequent cancer following breast cancer in men.& J Natl Cancer Inst. 2002;94(17):1330–1332.

28. Dong C, Hemminki K. Second primary breast cancer in men.& Breast Cancer Res Treat. 2001;66(2):171–172.

29. Cutuli B, Le-Nir CC, Serin D, et al. Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases.& Crit Rev Oncol Hematol. 2010;73(3):246–254.

30. Masci G, Caruso M, Caruso F, et al. Clinicopathological and immunohistochemical characteristics in male breast cancer: a retrospective case series.& Oncologist. 2015;20(6):586–592.

31. Anderson DE, Badzioch MD. Familial breast cancer risks. Effects of prostate and other cancers.& Cancer. 1993;72(1):114–119.

32. Anderson DE, Badzioch MD. Breast cancer risks in relatives of male breast cancer patients.& J Natl Cancer Inst. 1992;84(14):1114–1117.

33. Thellenberg C, Malmer B, Tavelin B, Grönberg H. Second primary cancers in men with prostate cancer: an increased risk of male breast cancer.& J Urol. 2003;169(4):1345–1348.

34. Hemminki K, Scélo G, Boffetta P, et al. Second primary malignancies in patients with male breast cancer.& Br J Cancer. 2005;92(7):1288–1292.

35. Lee UJ, Jones JS. Incidence of prostate cancer in male breast cancer patients: a risk factor for prostate cancer screening.& Prostate Cancer Prostatic Dis. 2009;12(1):52–56.

36. Network NCC.& Breast Cancer.& NCCN Clinical Practice Guidelines in Oncology; 2015. Available from: Accessed June 26, 2015.

37. Basham VM, Lipscombe JM, Ward JM, et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer.& Breast Cancer Res. 2002;4(1):R2.

38. Thorlacius S, Sigurdsson S, Bjarnadottir H, et al. Study of a single BRCA2 mutation with high carrier frequency in a small population.& Am J Hum Genet. 1997;60(5):1079–1084.

39. Sverdlov RS, Barshack I, Bar Sade RB, et al. Genetic analyses of male breast cancer in Israel.& Genet Test. 2000;4(3):313–317.

40. Giordano SH. A review of the diagnosis and management of male breast cancer.& Oncologist. 2005;10(7):471–479.

41. Berry DA, Iversen ES Jr, Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.& J Clin Oncol. 2002;20(11):2701–2712.

42. Euhus DM, Smith KC, Robinson L, et al. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.& J Natl Cancer Inst. 2002;94(11):844–851.

43. Huo D, Senie RT, Daly M, et al. Prediction of BRCA mutations using the BRCAPRO model in clinic-based African American, Hispanic, and other minority families in the United States.& J Clin Oncol. 2009;27(8):1184–1190.

44. Mitri ZI, Jackson M, Garby C, et al. BRCAPRO 6.0 model validation in male patients presenting for BRCA testing.& Oncologist. 2015; 20(6):593–597.

45. Neuhausen S, Dunning A, Steele L, et al. Role of CHEK2*1100delC in unselected series of non-BRCA1/2 male breast cancers.& Int J Cancer. 2004;108(3):477–478.

46. Boyd J, Rhei E, Federici MG, et al. Male breast cancer in the hereditary nonpolyposis colorectal cancer syndrome.& Breast Cancer Res Treat. 1999;53(1):87–91.

47. Network NCC.& Genetic/Familial High-Risk Assessment:& Breast and Ovarian. NCCN Clinical Practice Guidelines in Oncology; 2015. Available from:& Accessed June 20, 2015.

48. Anelli TF, Anelli A, Tran KN, Lebwohl DE, Borgen PI. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients.& Cancer. 1994;74(1):74–77.

49. Visram H, Kanji F, Dent SF. Endocrine therapy for male breast cancer: rates of toxicity and adherence.& Curr Oncol. 2010;17(5):17–21.

50. Pemmaraju N, Munsell MF, Hortobagyi GN, Giordano SH. Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects.& Ann Oncol. 2012;23(6):1471–1474.

51. Becker T, Lipscombe L, Narod S, Simmons C, Anderson GM, Rochon PA. Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer.& J Am Geriatr Soc. 2012;60(9):1761–1767.

52. Bauer M, Bryce J, Hadji P. Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer.& Breast Cancer. 2012;4:91–101.

53. Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.& J Clin Oncol. 2008;26(7):1051–1057.

54. Coleman RE, Banks LM, Girgis SI, et al; Intergroup Exemestane Study Group. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.& Lancet Oncol. 2007;8(2):119–127.

55. Howell A, Cuzick J, Baum M, et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer.& Lancet. 2005;365(9453):60–62.

56. Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.& Med J Aust. 2011;194(6):301–306.

57. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer.& JAMA. 2005;294(2):238–244.

58. Smith MR. Androgen deprivation therapy for prostate cancer: new concepts and concerns.& Curr Opin Endocrinol Diabetes Obes. 2007;14(3):247–254.

59. Greenspan SL. Approach to the prostate cancer patient with bone disease.& J Clin Endocrinol Metab. 2008;93(1):2–7.

60. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.& Cancer. 2004;100(5):892–899.

61. Higano CS. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?& Nat Clin Pract Urol. 2008;5(1):24–34.

62. Hamilton EJ, Ghasem-Zadeh A, Gianatti E, et al. Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy.& J Clin Endocrinol Metab. 2010;95(12):E456–E463.

63. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.& J Clin Endocrinol Metab. 2005;90(12):6410–6417.

64. Morote J, Orsola A, Abascal JM, et al. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.& J Urol. 2006;175(5):1679–1683. [discussion 1683].

65. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.& J Clin Oncol. 2005;23(31):7897–7903.

66. Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer.& J Urol. 2006;175(1):136–139. [discussion 139].

67. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer.& N Engl J Med. 2005;352(2):154–164.

68. Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.& Cancer. 2009;115(11):2388–2399.

69. Network NCC.& Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology; 2015. Available from: Accessed July 2, 2015.

70. Bordeleau L, Pritchard KI, Loprinzi CL, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors.& J Clin Oncol. 2010;28(35):5147–5152.

71. Sideras K, Loprinzi CL. Nonhormonal management of hot flashes for women on risk reduction therapy.& J Natl Compr Canc Netw. 2010; 8(10):1171–1179.

72. Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis.& J Clin Oncol. 2009;27(17):2831–2837.

73. Loprinzi CL, Barton DL, Sloan JA, et al. Mayo clinic and north central cancer treatment group hot flash studies: a 20-year experience.& Menopause. 2008;15(4 pt 1):655–660.


Schow DA, Renfer LG, Rozanski TA, Thompson IM. Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer.& South Med J. 1998;91(9):855–857.

75. Karling P, Hammar M, Varenhorst E. Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma.& J Urol. 1994;152(4):1170–1173.


Quella SK, Loprinzi CL, Sloan J, et al. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer.& J Urol. 1999;162(1):98–102.

77. Irani J, Salomon L, Oba R, Bouchard P, Mottet N. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial.& Lancet Oncology. 2010;11(2):147–154.

78. Frisk J. Managing hot flushes in men after prostate cancer – a systematic review.& Maturitas. 2010;65(1):15–22.

79. Smith JA Jr. A prospective comparison of treatments for symptomatic hot flushes following endocrine therapy for carcinoma of the prostate.& J Urol. 1994;152(1):132–134.

80. Eaton AC, McGuire N. Cyproterone acetate in treatment of post-orchidectomy hot flushes. Double-blind cross-over trial.& Lancet. 1983;2(8363):1336–1337.

81. Atala A, Amin M, Harty JI. Diethylstilbestrol in treatment of postorchiectomy vasomotor symptoms and its relationship with serum follicle-stimulating hormone, luteinizing hormone, and testosterone.& Urology. 1992;39(2):108–110.

82. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes.& N Engl J Med. 1994;331(6):347–352.

83. Frisk J, Spetz AC, Hjertberg H, Petersson B, Hammar M. Two modes of acupuncture as a treatment for hot flushes in men with prostate cancer – a prospective multicenter study with long-term follow-up.& Eur Urol. 2009;55(1):156–163.

84. Filshie J, Bolton T, Browne D, Ashley S. Acupuncture and self acupuncture for long-term treatment of vasomotor symptoms in cancer patients – audit and treatment algorithm.& Acupunct Med. 2005;23(4):171–180.

85. Ruddy KJ, Giobbie-Hurder A, Giordano SH, et al. Quality of life and symptoms in male breast cancer survivors.Breast. 2013;22(2):197–199.

86. Cappelleri JC, Rosen RC. The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience.& Int J Impot Res. 2005;17(4):307–319.

87. Kipling M, Ralph JE, Callanan K. Psychological impact of male breast disorders: literature review and survey results.& Breast Care. 2014;9(1):29–33.

88. Farrell E, Borstelmann N, Meyer F, Partridge A, Winer E, Ruddy K. Male breast cancer networking and telephone support group: a model for supporting a unique population.& Psychooncology. 2014;23(8):956–958.

89. Network NCC.& Survivorship.& NCCN Clinical Practie Guidelines in Oncology; 2015. Available from:

90. Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.& Circulation. 2015;131(22):1981–1988.

91. Nevasaari K, Heikkinen M, Taskinen PJ. Tamoxifen and thrombosis.& Lancet. 1978;2(8096):946–947.

92. Lipton A, Harvey HA, Hamilton RW. Venous thrombosis as a side effect of tamoxifen treatment.& Cancer Treat Rep. 1984;68(6):887–889.


Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review.& Cancer. 2004;101(3):439–449.

94. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.& J Natl Cancer Inst. 1998; 90(18):1371–1388.


Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial.& Lancet. 1998;352(9122):98–101.

96. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study.& Lancet. 1998;352(9122):93–97.

97. Wells PS, Forster AJ. Thrombolysis in deep vein thrombosis: is there still an indication?& Thromb Haemost. 2001;86(1):499–508.

98. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis.& Ann Intern Med. 1996; 125(1):1–7.

99. Goldhaber SZ. Pulmonary embolism.& N Engl J Med. 1998; 339(2):93–104.

100. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale.& Thromb Haemost. 2000;83(5):657–660.

101. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study.& Archives of Internal Medicine. 1991;151(5):933–938.

102. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study.& Arch Intern Med. 1998;158(6):585–593.

103. Heit JA.& Epidemiology of Venous Thromboembolism. Nature reviews.& Cardiology. 2015;12:464–474.

104. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study.& J Thromb Haemost. 2007; 5(4):692–699.

105. Serra R, Buffone G, Perri P, Renne M, Amato B, de Franciscis S. Male breast cancer manifesting as cephalic vein thrombosis.& Ann Vasc Surg. 2013;27(8):e9–e11.

Source: Breast Cancer: Targets and Therapy
Originally published on November 23 2015.